An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 5, 2014, Pages 522-529

  Psaros, Christina ^a,b   Haberer, Jessica E ^a,b   Katabira, Elly ^c   Ronald, Allan ^d   Tumwesigye, Elioda ^e   Campbell, James D ^f   Wangisi, Jonathan ^f   Mugwanya, Kenneth ^g   Kintu, Alex ^e,h   Enyakoit, Michael ⁱ   Thomas, Katherine K ^g   Donnell, Deborah ^g,j   Krows, Meighan ^g   Kidoguchi, Lara ^g   Ware, Norma ^b   Baeten, Jared M ^g   Celum, Connie ^g   Bangsberg, David R ^a,b,i,k   Safren, Steve A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

^d UNIVERSITY OF MANITOBA   (Canada)

^e Kabwohe Clinical Research Center   (Uganda)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^j Fred Hutchinson Cancer Research Center   (United States)

^k MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

more..

Author keywords

Adherence; HIV prevention; Intervention; Preexposure prophylaxis; Serodiscordant couples

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR;

ADULT; ARTICLE; BEHAVIOR THERAPY; COGNITIVE THERAPY; CONTROLLED STUDY; COUNSELING; DOUBLE BLIND PROCEDURE; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SERODISCORDANT COUPLE; SEXUALITY; UGANDA;

ADULT; ANTI-HIV AGENTS; COUNSELING; FAMILY CHARACTERISTICS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; UGANDA;

EID: 84904515959     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000212     Document Type: Article

References (30)

1. UNAIDS. AIDS Epidemic Update. 2011. Available at: http://www. unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/ 20121120-FactSheet-Global-en.pdf. Accessed June 2, 2014.
2. Van der Straten A, Van Damme L, Haberer JE, et al. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26:F13-F19.
3. Microbicide Trials Network. MTN-003-VOICE. 2013. Available at: http://www.mtnstopshiv.org/news/studies/mtn003.
4. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in Women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta. Abstract 26LB.
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
6. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
7. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
8. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
9. Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10: e1001511.
10. Ware NC, Wyatt MA, Haberer JE, et al. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59: 463-468.
11. García-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5:e28.
12. Safren SA, Otto MW, Worth JL. Life-steps: applying cognitive behavioral therapy to HIV medication adherence. Cogn Behav Pract. 1999;6: 332-341.
13. Safren SA, O'Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28:1-10.
14. D'Zurilla TJ. Problem-Solving Therapy: A Social Competence Approach to Clinical Intervention. New York: Springer; 1986.
15. Nezu A, D'Zurilla T. Social problem solving and negative affective conditions. In: Kendall P, Watson D, eds. Anxiety and Depression: Distinctive and Overlapping Features. New York, NY: Academic Press; 1989:285-315.
16. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365:493-505.
17. Campbell MS, Mullins JI, Hughes JP, et al. Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One. 2011;6:e16986.
18. Haberer JE, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14:1340-1346.
19. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366
20. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100-1102.
21. Filmer D, Pritchett LH. Estimating wealth effects without expenditure data-or tears: an application to educational enrollments in states of India. Demography. 2001;38:115.
22. Cherpitel CJ, Ye Y, Bond J, et al. Cross-national performance of the RAPS4/RAPS4-QF for tolerance and heavy drinking: data from 13 countries. J Stud Alcohol. 2005;66:428-432.
23. Lurie MN, Williams BG, Zuma K, et al. The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis. 2003;30:149-156.
24. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151ra125.
25. Louissaint NA, Cao Y-J, Skipper PL, et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses. 2013;29:1443-1450.
26. Heffron R, Ngure K, Mugo N, et al. Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies. J Acquir Immune Defic Syndr. 2012;61:116-119.
27. Adakun SA, Siedner MJ, Muzoora C, et al. Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. J Acquir Immune Defic Syndr. 2013;62: 317-321.
28. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362:427-439.
29. West SG, Duan N, Pequegnat W, et al. Alternatives to the randomized controlled trial. Am J Public Health. 2008;98:1359-1366.
30. Guidance on Pre-exposure Oral Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women Who Have Sex with Men at High Risk of HIV: Recommendations for Use in the Context of Demonstration Projects. Geneva, Switzerland: World Health Organization; 2012. Available at: http://www.ncbi.nlm. nih.gov/books/NBK132003/. Accessed November 7, 2013.